Complications of TreatmentManagement of toxicities of immune checkpoint inhibitors
Introduction
Immune checkpoint inhibitors (ICPIs) have changed the landscape of advanced cancer treatment during the last few years. Blockade with antibodies against cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-protein 1 (PD-1) or its ligand (PD-L1) augment the immunologic reaction against tumour cells in several cancer types.
CTLA-4 is part of the B7:CD28 immunoglobulin family found on the surface of T-cells and transmits an inhibitory signal to the T-cell. Ipilimumab is a fully human monoclonal antibody against CTLA-4 binding of which leads to deactivation of the inhibitory signal of the T-cell [1]. PD-1 is expressed on T-cells and binds to its ligands PD-L1 and PD-L2 that are expressed on cancer cells and other immune cells. Antibodies against PD-1, such as nivolumab, pembrolizumab and pidilizumab, or PD-L1, such as MEDI4736 and MPDL3280A increase the anti-tumour T-cell response by blocking the interaction of PD1 and PD-L1 to prevent T-cell inactivation [1].
Immune-related adverse events (irAEs) from ICPIs occur as a consequence of impaired self-tolerance from loss of T-cell inhibition. They can potentially involve every organ system but gastrointestinal, dermatologic, hepatic and endocrine toxicities predominate. These side effects are generally manageable but can be fatal in some cases [2], [3], [4], [5]. Their appearance may be subclinical and early diagnosis and management present challenges for the physician.
This article will focus on published toxicity data in phase II and III studies, the majority of which comes from trials in advanced melanoma, and present an approach to management of the main irAEs.
Section snippets
Melanoma
The greatest evidence for the use of ICPIs comes from studies in advanced melanoma. In the metastatic setting, ipilimumab [2], [6], nivolumab [7], [8] and pembrolizumab [5], [9] are all associated with a substantial survival advantage over cytotoxic chemotherapy in both pre-treated and treatment-naïve patients. Pembrolizumab and nivolumab are superior to ipilimumab in the first-line setting with regards to overall and progression-free survival respectively [5], [10]. Combination immunotherapy
General approach to management of irAEs
The disadvantage of an augmented immune response driven by T cell activation is the potential autoimmune-related inflammation of normal tissues. In most circumstances, this may be managed with immune-modulatory medications (IMM). When treating patients with ICPIs it is important to remain open-minded to the possibility of irAEs, both rare and common, and develop a careful approach to their assessment and management. This includes comprehensive education of patients and care-givers on
Diarrhoea and enterocolitis
Diarrhoea is one of the most frequent AEs related to ICPIs. It occurs at any grade in 23–33% of patients treated with ipilimumab, 8–19% of those managed with anti-PD-1 antibodies and 44% with the combination of ipilimumab and nivolumab [5], [7], [8], [10], [19]. Grade 3 and 4 diarrhoea is most prevalent with the combination approach (9%) [10]. The term colitis is used to describe diarrhoea associated with abdominal pain, per rectal bleeding or mucous, or when imaging findings confirm large
Discussion
Immune-checkpoint inhibitors have improved overall survival in a number of malignancies and have an established role in the treatment of advanced melanoma, non-small cell lung cancer and renal cancer. They commonly cause irAEs, some of which are severe, but are usually reversible with early recognition and specialised management. Algorithms for the management of irAEs have been developed and these provide a framework within which individual clinicians may exercise their discretion. Where
Conflict of interest
There are no specific conflicts of interests to declare for any of the authors (L. Spain, S. Diem, J. Larkin).
Disclosures for J.L. include: non-remunerated consultant for Novartis, Pfizer, BMS, MSD and Roche/Genentech and receives institutional research support from Pfizer, BMS, Novartis, MSD.
No funding has been received in relation to this article.
References (91)
- et al.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
(2014) - et al.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Lancet Oncol
(2015) - et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Lancet Oncol
(2015) - et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Lancet Oncol
(2015) - et al.
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Lancet Oncol
(2010) - et al.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Lancet
(2014) - et al.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Lancet Oncol
(2015) - et al.
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Lancet Oncol
(2013) - et al.
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
Lancet Respir Med
(2015) - et al.
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Lancet Oncol
(2014)
Association between ipilimumab and celiac disease
Mayo Clin Proc
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis
J Am Acad Dermatol
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
J Am Acad Dermatol
Ipilimumab-associated Sweet syndrome in a melanoma patient
J Am Acad Dermatol
Lambrolizumab induced central nervous system (CNS) toxicity
J Neurol Sci
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
J Am Acad Dermatol
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
Ann Oncol
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Proc Natl Acad Sci USA
Improved survival with ipilimumab in patients with metastatic melanoma
N Engl J Med
Pembrolizumab versus ipilimumab in advanced melanoma
N Engl J Med
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
N Engl J Med
Nivolumab in previously untreated melanoma without BRAF mutation
N Engl J Med
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
N Engl J Med
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
N Engl J Med
Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
J Clin Oncol
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
N Engl J Med
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Lancet
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
N Engl J Med
Pembrolizumab for the treatment of non-small-cell lung cancer
N Engl J Med
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial
J Clin Oncol
Nivolumab versus everolimus in advanced renal-cell carcinoma
N Engl J Med
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma
N Engl J Med
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
J Clin Oncol
PD-1 blockade in tumors with mismatch-repair deficiency
N Engl J Med
Management of immune-related adverse events and kinetics of response with ipilimumab
J Clin Oncol
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Endocr Relat Cancer
Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center
Cancer Immunol Res
Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy
J Clin Oncol
Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
BMC Cancer
Ipilimumab-associated colitis: CT findings
AJR Am J Roentgenol
Cited by (665)
Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
2023, Gynecologic Oncology ReportsThe efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis
2025, Journal of Cancer Research and Clinical OncologyProfound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report
2024, Journal of Medical Case ReportsGlioblastoma Therapy: Past, Present and Future
2024, International Journal of Molecular SciencesDecoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals
2024, Cell Biochemistry and Function